B
IOVA icon

Braidwell’s Iovance Biotherapeutics IOVA Stock Holding History

Braidwell’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-217,928
Closed -$2.05M – 84
2024
Q3 		$2.05M Sell
217,928
-1,248,682
-85% -$11.8M 0.06% 77
2024
Q2 		$11.8M Buy
1,466,610
+806,588
+122% +$8.64M 0.37% 53
2024
Q1 		$9.78M Buy
+660,022
New +$7.68M 0.32% 61

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Braidwell's IOVA Position: Q4 2024 in Review

Braidwell sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 217,928 shares — an estimated $2.05M sold.

Braidwell first reported a position in IOVA in Q1 2024 and held it in 3 quarters. The position peaked at $11.8M in Q2 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Braidwell reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Braidwell sold 217,928 Iovance Biotherapeutics shares in Q4 2024, an estimated $2.05M.
  • Braidwell first reported a position in Iovance Biotherapeutics in Q1 2024 and held it in 3 quarters.
  • Braidwell's Iovance Biotherapeutics position peaked at $11.8M in Q2 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Braidwell's 13F filing for Q4 2024, filed 14 Feb 2025.